Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126096081 | 12609608 | 1 | I | 20131118 | 0 | 20160729 | 20160729 | DIR | 29.00 | YR | F | N | 170.00000 | LBS | 20160728 | N | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126096081 | 12609608 | 1 | PS | AVELOX | MOXIFLOXACIN HYDROCHLORIDE | 1 | Oral | ONCE A DAY TAKEN BY MOUTH | Y | Y | 0 | ||||||||
126096081 | 12609608 | 3 | C | IBUPROFEN. | IBUPROFEN | 1 | 0 | ||||||||||||
126096081 | 12609608 | 5 | C | ONE-A-DAY MULTIVITAMIN | 2 | 0 | |||||||||||||
126096081 | 12609608 | 7 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126096081 | 12609608 | 1 | Pilonidal cyst |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126096081 | 12609608 | DS |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126096081 | 12609608 | Arthralgia | |
126096081 | 12609608 | Condition aggravated | |
126096081 | 12609608 | Joint dislocation | |
126096081 | 12609608 | Ligament disorder | |
126096081 | 12609608 | Tendon disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
Event ID | CASEID | RPSR COD |
---|---|---|
126096081 | 12609608 | HP |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126096081 | 12609608 | 1 | 20131118 | 0 |